Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies
Your provider will help determine which option is best for your health profile
The phase 2b SYMMETRY trial, a multicenter, randomized, double-blind, placebo-controlled study, included 181 patients with compensated cirrhosis (Child-Pugh A) due to MASH (78% with histological diagnosis and 22% with cryptogenic cirrhosis attributed to MASH) assigned to receive efruxifermin at doses of 28 or 50 mg, or placebo (1:1:1), for 96 weeks
In Southern California, we were, we were trained to take care of the patient's needs and medications
35 For instance, metabolic-bariatric surgery is covered by more than 90% of US private insurers for patients meeting criteria, 35 whereas endoscopic therapies are generally not covered by insurance and may require full out-of-pocket payment